Tag Archives: life sciences

ISPOR Europe: Closing the gap between research and actionable outputs

Last month, thousands of global researchers, thought leaders and life sciences industry peers gathered in Italy for the 18th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). We were all there in the name of health economics and outcomes research, which is very appropriate given that health economics was first […]
Read More »

Adapting epidemiologic principles to “big data”

Optum’s epidemiology experts apply the rigor of advanced epidemiologic methods to the challenges inherent in “big data” The term “big data” is ubiquitous these days. Within healthcare, electronic data from administrative systems and electronic health records (EHRs) are increasingly voluminous, varied and accessible. Within health care and public health, our capacity to use data has […]
Read More »

ISPOR, Optum and the Power of Real-World Data

The life sciences industry is facing unprecedented opportunities and challenges, and I’m excited. We’re entering new and diverse markets, unlike any we’ve experienced before, while at the same time the dynamics in existing markets are becoming more complex due to health care transformation efforts.

ISPOR: Focusing on the Patient

For the past 17 years, attendance at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting has grown from under 500 in attendance at the first conference held in 1996 to an expected turnout of more than 3,000 during the May 18-22, 2013 meeting in New Orleans.

Do You Hate to be Late? Most People Do

In most every aspect of our lives, it pays to be on time. This is especially true for pharmaceutical companies under pressure to complete clinical trials quickly and effectively so they can bring new drugs to market sooner. Unfortunately, clinical trials often are subject to costly delays, caused by the challenges inherent in finding the […]
Read More »